Liminatus Pharma, Inc.
LIMN
$5.54
-$0.61-9.92%
NASDAQ
| 12/31/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Net Income | 70.30% | 12.78% | |||
| Total Depreciation and Amortization | -- | -- | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | -- | -- | |||
| Change in Net Operating Assets | -80.53% | 504.11% | |||
| Cash from Operations | 55.80% | 53.24% | |||
| Capital Expenditure | -- | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -17.27% | -- | |||
| Cash from Investing | -17.27% | -- | |||
| Total Debt Issued | -50.00% | 100.00% | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | -41.67% | 138.80% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -97.82% | 91.61% | |||